Wave Life Sciences ( (WVE) ) has shared an update.
Wave Life Sciences is advancing its RNA-based therapeutic pipeline with promising updates, including the WVE-007 program for obesity and new RNA editing programs targeting cardiometabolic diseases. The company plans to initiate a clinical trial for WVE-007 in early 2025, showcasing its potential as a monotherapy or in combination with GLP-1s. Wave is also leading innovations in RNA editing and intracellular delivery, aiming to address significant unmet needs in the healthcare market.
For detailed information about WVE stock, go to TipRanks’ Stock Analysis page.
